Late-stage clinical development in lower urogenital targets: sexual dysfunction

Area of Science:

• Urology
• Pharmacology
• Clinical Research

Background:

• Late-stage drug development targets male sexual dysfunction (MSD), female sexual dysfunction (FSD), prostatic pathology, and lower urinary tract symptoms.
• Existing treatments for erectile dysfunction (ED), benign prostatic hyperplasia, overactive bladder, and stress urinary incontinence have limitations.
• There is a need for improved therapies addressing lower urogenital tract sexual conditions.

Purpose of the Study:

• To review late-stage human clinical development in male sexual dysfunction (MSD) and female sexual dysfunction (FSD).
• To highlight advancements in understanding and treating conditions like premature ejaculation and erectile dysfunction.
• To discuss progress in assessing treatment benefits for female sexual dysfunction.

Main Methods:

• Review of late-stage clinical trials focusing on urogenital targets.
• Analysis of recent developments in drug discovery for MSD and FSD.
• Examination of challenges in diagnosing and treating FSD.

Main Results:

• Significant progress in MSD development, particularly for premature ejaculation.
• Ongoing research for improved efficacy and safety in erectile dysfunction treatments.
• Advancements in clinical trial methodologies for assessing FSD treatment benefits.

Conclusions:

• Late-stage clinical development is actively addressing unmet needs in MSD and FSD.
• Further research is needed for novel therapies with enhanced efficacy and safety profiles.
• Improved diagnostic and assessment tools are crucial for effective FSD treatment.